Benjamin Israelow
Overview
Explore the profile of Benjamin Israelow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
5196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, et al.
J Exp Med
. 2025 Feb;
222(4).
PMID: 40009071
No abstract available.
2.
Seo J, Polster J, Israelow B, Corbett-Helaire K, Martinez D
Nat Biotechnol
. 2024 Dec;
42(12):1765-1767.
PMID: 39643701
No abstract available.
3.
Pena-Hernandez M, Alfajaro M, Filler R, Moriyama M, Keeler E, Ranglin Z, et al.
Nat Microbiol
. 2024 Jul;
9(8):2038-2050.
PMID: 39075235
Circulating bat coronaviruses represent a pandemic threat. However, our understanding of bat coronavirus pathogenesis and transmission potential is limited by the lack of phenotypically characterized strains. We created molecular clones...
4.
5.
Mao T, Kim J, Pena-Hernandez M, Valle G, Moriyama M, Luyten S, et al.
Proc Natl Acad Sci U S A
. 2024 Apr;
121(18):e2319566121.
PMID: 38648490
Respiratory virus infections in humans cause a broad-spectrum of diseases that result in substantial morbidity and mortality annually worldwide. To reduce the global burden of respiratory viral diseases, preventative and...
6.
Suberi A, Grun M, Mao T, Israelow B, Reschke M, Grundler J, et al.
Sci Transl Med
. 2023 Aug;
15(709):eabq0603.
PMID: 37585505
An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung-targeted mRNA therapeutics has been limited by...
7.
Mao T, Israelow B, Pena-Hernandez M, Suberi A, Zhou L, Luyten S, et al.
Science
. 2022 Oct;
378(6622):eabo2523.
PMID: 36302057
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity...
8.
Fernandez-Castaneda A, Lu P, Geraghty A, Song E, Lee M, Wood J, et al.
Cell
. 2022 Jun;
185(14):2452-2468.e16.
PMID: 35768006
COVID survivors frequently experience lingering neurological symptoms that resemble cancer-therapy-related cognitive impairment, a syndrome for which white matter microglial reactivity and consequent neural dysregulation is central. Here, we explored the...
9.
Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, et al.
Nature
. 2022 Apr;
606(7914):585-593.
PMID: 35483404
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine production, viral RNA and a sustained interferon (IFN) response, all of which are recapitulated and required for pathology in the...
10.
Suberi A, Grun M, Mao T, Israelow B, Reschke M, Grundler J, et al.
bioRxiv
. 2022 Mar;
PMID: 35350207
One-sentence Summary: Inhaled polymer nanoparticles (NPs) achieve high mRNA expression in the lung and induce protective immunity against SARS-CoV-2.